Earnings Results
Myriad Genetics (NASDAQ:MYGN) reported quarterly earnings results on July 30, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.25, missing the consensus estimate of $-0.06 by $0.19 per share. Revenue came in at $190.7M, missing the estimate of $205.9M.
Company Overview
Myriad Genetics's stock moved following the earnings release. The stock currently trades at $5.37 with a market capitalization of $680.9M.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 317% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Myriad Genetics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
Myriad Genetics Earnings History
| Quarter | EPS Actual | EPS Est. | Surprise |
| Q2 (Jul 2026) | $-0.25 | $-0.06 | -316.7% |
| Q1 (May 2026) | $-0.09 | $-0.09 | +0.0% |
| Q4 (Feb 2026) | $0.04 | $-0.05 | +180.0% |
Related Tools: Earnings Calendar | View MYGN Stock Page
Frequently Asked Questions
When does Myriad Genetics report earnings?
Check the latest earnings dates on our MYGN earnings page or the Earnings Calendar.
Did MYGN beat earnings estimates?
See the full Q2 results including EPS actual vs estimate on our MYGN earnings page.